Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fraser Wright

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Human Gene Therapy Methods|March 21, 2012
Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methodsPaolo Fagone, J Fraser Wright, Amit C Nathwani, et al.
The Journal of Gene Medicine|December 13, 2006
Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cellsKeefe Chng, Stephen R Larsen, Shangzhen Zhou, et al.
Journal of Virology|October 22, 2002
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transductionHiroyuki Nakai, Clare E Thomas, Theresa A Storm, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector deliveryHarrison C Brown, J Fraser Wright, Shangzhen Zhou, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2009
Host and vector-dependent effects on the risk of germline transmission of AAV vectorsPatricia Favaro, Harre D Downey, J Shangzhen Zhou, et al.
Plos One|June 25, 2015
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid ArthritisCaroline J Aalbers, Lisette Bevaart, Scott Loiler, et al.
Molecular Therapy. Methods & Clinical Development|February 25, 2016
Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia AAllison M Lytle, Harrison C Brown, Na Yoon Paik, et al.
Human Gene Therapy|January 18, 2006
Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophiliaBernd Hauck, Ray Ruian Xu, Jing Xie, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 8, 2003
Quantification of adeno-associated virus particles and empty capsids by optical density measurementJürg M Sommer, Peter H Smith, Sumathy Parthasarathy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2005
Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulationJ Fraser Wright, Tannie Le, Joseph Prado, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Human Gene Therapy Methods|March 21, 2012
Systemic errors in quantitative polymerase chain reaction titration of self-complementary adeno-associated viral vectors and improved alternative methodsPaolo Fagone, J Fraser Wright, Amit C Nathwani, et al.
The Journal of Gene Medicine|December 13, 2006
Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cellsKeefe Chng, Stephen R Larsen, Shangzhen Zhou, et al.
Journal of Virology|October 22, 2002
A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transductionHiroyuki Nakai, Clare E Thomas, Theresa A Storm, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector deliveryHarrison C Brown, J Fraser Wright, Shangzhen Zhou, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 19, 2009
Host and vector-dependent effects on the risk of germline transmission of AAV vectorsPatricia Favaro, Harre D Downey, J Shangzhen Zhou, et al.
Plos One|June 25, 2015
Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid ArthritisCaroline J Aalbers, Lisette Bevaart, Scott Loiler, et al.
Molecular Therapy. Methods & Clinical Development|February 25, 2016
Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia AAllison M Lytle, Harrison C Brown, Na Yoon Paik, et al.
Human Gene Therapy|January 18, 2006
Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophiliaBernd Hauck, Ray Ruian Xu, Jing Xie, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 8, 2003
Quantification of adeno-associated virus particles and empty capsids by optical density measurementJürg M Sommer, Peter H Smith, Sumathy Parthasarathy, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2005
Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulationJ Fraser Wright, Tannie Le, Joseph Prado, et al.
Pageof 7